Advertisement

Shorter Survival of Patients with Upper-Third Gastric Cancer Preoperatively Diagnosed as Stage IA Compared with Those with Middle to Lower Lesions

  • Tatsuo Matsuda
  • Manabu OhashiEmail author
  • Masahiro Tsujiura
  • Satoshi Ida
  • Koshi Kumagai
  • Souya Nunobe
  • Takeshi Sano
  • Naoki Hiki
Peritoneal Surface Malignancy
  • 19 Downloads

Abstract

Background

Although preoperatively diagnosed stage IA (cT1N0) gastric cancer includes pathologically advanced disease, patients with cT1N0 middle- to lower-third gastric cancer (MLTG) experience favorable outcomes even if they undergo gastrectomy with limited lymph node dissection; however, whether this is true for upper-third gastric cancer (UTG) patients is unknown. In this study, we examined the survival of patients with cT1N0 UTG compared with patients with MLTG.

Methods

We retrospectively reviewed the data for 1707 consecutive patients with cT1N0 gastric cancer who underwent gastrectomy between 2006 and 2013. Patients were divided into the UTG or MLTG groups, and clinicopathological characteristics and survival were compared between the groups. Factors affecting survival were identified using multivariate analysis. Survival was calculated according to pathological findings.

Results

The patient group included 334 UTG patients and 1373 MLTG patients. The 5-year overall survival (OS) of UTG patients was significantly shorter than that of MLTG patients, and UTG was identified as an independent prognostic factor of cT1N0 gastric cancer. Among UTG cases, the OS of pT2–4 or pN1–3 was significantly shorter than that of pT1 or pN0 disease. No significant differences were found between such diseases in MLTG. All relapses in UTG were distant metastases.

Conclusions

cT1N0 UTG with pT2–4 or pN1-3 are prognostic indicators of shorter OS, although MLTG of either disease is associated with favorable prognosis. Thus, UTG is an independent prognostic factor in cT1N0 gastric cancer; however, limited dissection is acceptable for cT1N0 UTG because relapses occur at distant sites.

Notes

Sources of Funding

None.

Disclosure

Tatsuo Matsuda, Manabu Ohashi, Masahiro Tsujiura, Satoshi Ida, Koshi Kumagai, Souya Nunobe, Takeshi Sano, and Naoki Hiki have no potential conflicts of interest to disclose.

References

  1. 1.
    Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359–86.CrossRefGoogle Scholar
  2. 2.
    Nashimoto A, Akazawa K, Isobe Y, et al. Gastric cancer treated in 2002 in Japan: 2009 annual report of the JGCA nationwide registry. Gastric Cancer. 2013;16(1):1–27.CrossRefGoogle Scholar
  3. 3.
    Japanese Gastric Cancer Treatment Guidelines 2014 (ver. 4). Gastric Cancer. 2017;20(1):1–19.Google Scholar
  4. 4.
    Lee JH, Lee KN, Kim HI, Kim MG, Ha TK, Kwon SJ. Discordant findings between preoperative endoscopy and postoperative pathology as an independent prognostic factor in gastric cancer patients. Surg Endosc. 2016;30(7):2743–50.CrossRefGoogle Scholar
  5. 5.
    Tsujiura M, Hiki N, Ohashi M, et al. Excellent long-term prognosis and favorable postoperative nutritional status after laparoscopic pylorus-preserving gastrectomy. Ann Surg Oncol. 2017;24(8):2233–40.CrossRefGoogle Scholar
  6. 6.
    Hiki N, Katai H, Mizusawa J, et al. Long-term outcomes of laparoscopy-assisted distal gastrectomy with suprapancreatic nodal dissection for clinical stage I gastric cancer: a multicenter phase II trial (JCOG0703). Gastric Cancer. 2018;21(1):155–61.CrossRefGoogle Scholar
  7. 7.
    Kim W, Kim HH, Han SU, et al. Decreased morbidity of laparoscopic distal gastrectomy compared with open distal gastrectomy for stage I gastric cancer: short-term outcomes from a multicenter randomized controlled trial (KLASS-01). Ann Surg. 2016;263(1):28–35.CrossRefGoogle Scholar
  8. 8.
    Jang JH, Beron RI, Ahn HS, et al. Clinicopathological features of upper third gastric cancer during a 21-year period (Single Center Analysis). J Gastric Cancer. 2010;10(4):212–18.CrossRefGoogle Scholar
  9. 9.
    Japanese Classification Of Gastric Carcinoma: 3rd English edition. Gastric Cancer. 2011;14(2):101–12.Google Scholar
  10. 10.
    Sakuramoto S, Sasako M, Yamaguchi T, et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med. 2007;357(18):1810–20.CrossRefGoogle Scholar
  11. 11.
    Ichikawa D, Komatsu S, Kosuga T, et al. Clinicopathological characteristics of clinical early gastric cancer in the upper-third stomach. World J Gastroenterol. 2015;21(45):12851–6.CrossRefGoogle Scholar
  12. 12.
    Kunisaki C, Shimada H, Nomura M, et al. Surgical outcome in patients with gastric adenocarcinoma in the upper third of the stomach. Surgery. 2005;137(2):165–71.CrossRefGoogle Scholar
  13. 13.
    Fujikawa H, Yoshikawa T, Hasegawa S, et al. Diagnostic value of computed tomography for staging of clinical T1 gastric cancer. Ann Surg Oncol. 2014;21(9):3002–7.CrossRefGoogle Scholar
  14. 14.
    Yamamoto S, Nishida T, Kato M, et al. Evaluation of endoscopic ultrasound image quality is necessary in endosonographic assessment of early gastric cancer invasion depth. Gastroenterol Res Pract. 2012;2012:194530.CrossRefGoogle Scholar
  15. 15.
    Tokunaga M, Hiki N, Fukunaga T, Ohyama S, Yamada K, Yamaguchi T. Better prognosis of T2 gastric cancer with preoperative diagnosis of early gastric cancer. Ann Surg Oncol. 2009;16(6):1514–9.CrossRefGoogle Scholar
  16. 16.
    Kano Y, Ohashi M, Ida S, et al. Oncological feasibility of laparoscopic subtotal gastrectomy compared with laparoscopic proximal or total gastrectomy for cT1N0M0 gastric cancer in the upper gastric body. Gastric Cancer. 2019;22(5):1060–8.CrossRefGoogle Scholar
  17. 17.
    Cancer Genome Atlas Research Network. Comprehensive molecular characterization of gastric adenocarcinoma. Nature. 2014;513(7517):202–9.CrossRefGoogle Scholar
  18. 18.
    Kurokawa Y, Matsuura N, Kimura Y, et al. Multicenter large-scale study of prognostic impact of HER2 expression in patients with resectable gastric cancer. Gastric Cancer. 2015;18(4):691–7.CrossRefGoogle Scholar
  19. 19.
    Fan XS, Chen JY, Li CF, et al. Differences in HER2 over-expression between proximal and distal gastric cancers in the Chinese population. World J Gastroenterol. 2013;19(21):3316–23.CrossRefGoogle Scholar

Copyright information

© Society of Surgical Oncology 2019

Authors and Affiliations

  • Tatsuo Matsuda
    • 1
  • Manabu Ohashi
    • 1
    Email author
  • Masahiro Tsujiura
    • 1
  • Satoshi Ida
    • 1
  • Koshi Kumagai
    • 1
  • Souya Nunobe
    • 1
  • Takeshi Sano
    • 1
  • Naoki Hiki
    • 1
  1. 1.Department of Gastroenterological Surgery, Gastroenterological Center, Cancer Institute HospitalJapanese Foundation for Cancer ResearchTokyoJapan

Personalised recommendations